Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cholinesterase inhibitors may help in mild Alzheimer's

Cholinesterase inhibitor drugs donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) can provide improved cognitive function, daily activity and behaviour to Alzheimer's disease patients with mild to moderate dementia, according to a review published online in The Cochrane Database of Systematic Reviews (25 January).

Jacqueline Birks, a medical statistician from the Cochrane Dementia and Cognitive Improvement Group at the University of Oxford, found that there was no clear differences between the three agents in terms of efficacy. Data suggest that donepezil has a superior adverse reaction profile, but Ms Birks postulates that galantamine and rivastigmine could have similar tolerability if doses were carefully and slowly adjusted over at least three months.

The systematic review offers some credence to the draft National Institute for Health and Clinical Excellence review that changes its preliminarily negative stance on the agents being available to NHS patients. However, Ms Birks suggests that NICE might have gone further. She told The Journal that, although there was little evidence to support the use of the agents in severe disease, they might have a place in mild disease. “Cholinesterase inhibitors have been shown to be effective in people with mild to moderate disease. And since patients with mild Alzheimer’s disease could benefit, that is, patients with a mini mental score higher than 20, there is no reason why they should be denied treatment with a cholinesterase inhibitor. The earlier the treatment is used in the disease, the longer the patient could benefit in terms of improved memory, more independence and less need for help and support”.

Citation: The Pharmaceutical Journal URI: 10020833

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • MCQs in Pharmaceutical Calculations

    MCQs in Pharmaceutical Calculations

    MCQs in Pharmaceutical Calculations will help you to perform calculations accurately and with confidence.

    £24.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmacy Registration Assessment Questions Package

    Pharmacy Registration Assessment Questions Package

    Pharmacy Registration Assessment Questions is a revision series featuring closed book and calculation questions. It can be used in conjunction with previous volumes or on its own to help you prepare for the GPHC exams.

    £80.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.